Related references
Note: Only part of the references are listed.Janus kinase 2 inhibitors in myeloproliferative disorders
Eugenio Lucia et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
Alfonso Quintas-Cardama et al.
BLOOD (2010)
DNA Damage-Mediated Induction of a Chemoresistant Niche
Luke A. Gilbert et al.
CELL (2010)
Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3
Kuen-Feng Chen et al.
CLINICAL CANCER RESEARCH (2010)
Mutational Status of Myeloproliferative Neoplasms
Elisa Rumi et al.
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION (2010)
KRAS Mutant Lung Cancer Cells Are Differentially Responsive to MEK Inhibitor Due to AKT or STAT3 Activation: Implication for Combinatorial Approach
Young-Kwang Yoon et al.
MOLECULAR CARCINOGENESIS (2010)
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim et al.
NATURE (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer
Zhan Yao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Synthetic Lethal Screen of an EGFR-Centered Network to Improve Targeted Therapies
Igor Astsaturov et al.
SCIENCE SIGNALING (2010)
Stat3: linking inflammation to epithelial cancer - more than a gut feeling?
Andrew Jarnicki et al.
CELL DIVISION (2010)
Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation
Kenneth Leslie et al.
BREAST CANCER RESEARCH (2010)
Amplification of chromosomal segment 4q12 in non-small cell lung cancer
Alex H. Ramos et al.
CANCER BIOLOGY & THERAPY (2009)
The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
Michael Hedvat et al.
CANCER CELL (2009)
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
David M. Jackman et al.
CLINICAL CANCER RESEARCH (2009)
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Pasi A. Jaenne et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers
Selvaraju Veeriah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation
Daniel J. Gough et al.
SCIENCE (2009)
STATs in cancer inflammation and immunity: a leading role for STAT3
Hua Yu et al.
NATURE REVIEWS CANCER (2009)
Environment-mediated drug resistance: a major contributor to minimal residual disease
Mark B. Meads et al.
NATURE REVIEWS CANCER (2009)
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Jeffrey A. Engelman et al.
CLINICAL CANCER RESEARCH (2008)
The Interleukin-8 Pathway in Cancer
David J. J. Waugh et al.
CLINICAL CANCER RESEARCH (2008)
Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group
Jean-Pierre Pignon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Somatic mutations affect key pathways in lung adenocarcinoma
Li Ding et al.
NATURE (2008)
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas
Sizhi Paul Gao et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Epidermal growth factor receptor activation: How exon 19 and 21 mutations changed our understanding of the pathway
Rafael Rosell et al.
CLINICAL CANCER RESEARCH (2006)
Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor
JV Alvarez et al.
CANCER RESEARCH (2006)
Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer
EB Haura et al.
CLINICAL CANCER RESEARCH (2005)
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
AV Jones et al.
BLOOD (2005)
Stat3 is required for full neoplastic transformation by The Simian Virus 40 Large Tumor Antigen
A Vultur et al.
MOLECULAR BIOLOGY OF THE CELL (2005)
Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-β signaling
BJ Jenkins et al.
NATURE MEDICINE (2005)
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target
R Chiarle et al.
NATURE MEDICINE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The stats of cancer - New molecular targets come of age
H Yu et al.
NATURE REVIEWS CANCER (2004)
SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer
B He et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC)
T Mukohara et al.
LUNG CANCER (2003)
Signaling by Type I and II cytokine receptors: ten years after
M Gadina et al.
CURRENT OPINION IN IMMUNOLOGY (2001)
Share Paper
